[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350430-105":59,"doc-detail-350430-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","heterogeneity-of-ex-vivo-tumor-responses-in-ovarian-cancer-tissues","Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues","","Advanced-stage ovarian cancers show wide variability in responses to standard chemotherapy, with outcomes spanning platinum-refractory to platinum-sensitive disease. Genomic testing can reveal tissue heterogeneity but often fails to deliver actionable guidance for therapy selection. This study evaluates functional profiling of ex vivo drug responses in primary ovarian cancer tissues using 3D microtumors and quantifies interpatient variability to support personalized treatment choice.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/heterogeneity-of-ex-vivo-tumor-responses-in-ovarian-cancer-tissues/350430/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/heterogeneity-of-ex-vivo-tumor-responses-in-ovarian-cancer-tissues/350430.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in ovarian cancer treatment?","Question",{"text":112,"@type":113},"The study targets the clinically observed variability in patient responses to standard chemotherapy, where some patients fail to benefit and outcomes differ widely across individuals.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How is tumor heterogeneity measured in the ex vivo experiments?",{"text":117,"@type":113},"Interpatient heterogeneity is quantified using the statistical variability of EC50 values derived from the ratio of upper and lower interdecile values.",{"name":119,"@type":110,"acceptedAnswer":120},"Which drugs showed the largest variability in single-agent responses?",{"text":121,"@type":113},"Gemcitabine exhibited the highest single-agent heterogeneity across the cohort, while doxorubicin and olaparib showed more consistent responses but limited efficacy in many samples.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350430,1790721455,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Cancer Reports  \nORIGINAL ARTICLE  OPEN ACCESS   \nHeterogeneity of Ex Vivo Tumor Responses  \nin Ovarian Cancer Tissues  \nChiara Maestri1  | Ivan Trus1,2  | Rajeshwar Nitiyanandan1  | Jahanvi Kumar1  | Ricardo J. Parker1,3  | Orazio De Tommasi4  | William Cance1,5  | Christian Apfel1,6   \n1SageMedic Corp, Redwood City, California, USA | 2International Institute of Molecular and Cell Biology, Warsaw, Poland | 3National University, San Diego, California, USA | 4Department of Women and Children's Health, Clinic of Gynecology and Obstetrics, University of Padova, Padova,  \nItaly | 5University of Arizona College of Medicine, Phoenix, Arizona, USA | 6University of California San Francisco, San Francisco, California, USA Correspondence: Chiara Maestri ([chiara@sagemedic.com](chiara@sagemedic.com)) | Christian Apfel ([capfel@sagemedic.com](capfel@sagemedic.com))  \nReceived: 14 August 2025 | Revised: 31 March 2026 | Accepted: 13 April 2026  \nKeywords: ex vivo drug testing | functional profiling | ovarian cancer | precision oncology | tumor heterogeneity  \nABSTRACT  \nBackground: Advanced-stage ovarian cancers exhibit significant variability in responses to standard chemotherapy ranging from platinum-refractory to platinum-sensitive cancers. While genomic testing reveals tissue heterogeneity, it rarely provides actionable data for guiding therapy.  \nAims: To evaluate the heterogeneity of ex vivo drug responses in primary ovarian cancer tissues using a functional profiling platform, and to assess the platform's potential for guiding personalized therapy selection within current clinical practice.  \nMethods and Results: A functional profiling platform that creates 3D microtumors from fresh biopsies was used to enable ex vivo assessment of drug efficacy in a physiologically relevant model. Interpatient heterogeneity was quantified as the statistical variability of the EC50 values, calculated using the ratio of upper and lower interdecile values. Seventeen ovarian cancer tissues were processed and exposed to NCCN-recommended drugs and drug combinations. Drug efficacy demonstrated significant interpatient heterogeneity (p \u003C 0.001) . Carboplatin and paclitaxel alone exhibited moderate heterogeneity (54-fold and 42-fold difference), while their combination showed higher heterogeneity (3880-fold difference), suggesting synergy in certain samples but not in others. Gemcitabine exhibited the highest single-agent heterogeneity across the cohort (1504-fold difference), whereas doxorubicin and olaparib demonstrated more consistent responses but limited efficacy in many samples (20-fold and 16-fold difference) . Conclusion: These findings align with the clinically observed variability in patient responses, highlighting the platform's potential to optimize therapy selection and support patient-centric care within the standard of care for ovarian cancer patients.  \n1 | Introduction  \nOvarian cancer remains a significant clinical challenge, particularly in advanced stages where therapeutic outcomes vary widely among patients. While most ovarian cancer patients initially respond favorably to the standard carboplatin and paclitaxel regimen, now also increasingly utilized in the neo-adjuvant setting to improve surgical outcomes, a subset of patients derives no benefit [1, 2] . For these patients, the side effects of ineffective chemotherapy, coupled with the delay in surgery, may result in  \nworse outcomes compared to immediate surgical intervention [3]. Similarly, in the adjuvant setting, some ovarian cancers recur within six months and are usually classified as platinum-resistant [4] . Furthermore, even among patients with cancers deemed platinum-sensitive, recurrence remains frequent, contributing toa poor overall prognosis and 5-year survival rate for advancedstage ovarian cancers of about 30%[5] . These challenges highlight the need for better tools to characterize the sensitivity and resistance profiles of each tumor and to better personalize the patie","cbCaigLqL8yO6Wk9","https://ap.wps.com/l/cbCaigLqL8yO6Wk9","pdf",969642,"English","# Introduction\n## Clinical variability and need for functional tools\n## Limitations of genomic profiling\n# Methods and Results\n## Ex vivo functional profiling platform\n## Quantifying interpatient heterogeneity\n## Drug-specific efficacy and heterogeneity patterns\n# Conclusion","[{\"question\":\"What problem does the study address in ovarian cancer treatment?\",\"answer\":\"The study targets the clinically observed variability in patient responses to standard chemotherapy, where some patients fail to benefit and outcomes differ widely across individuals.\"},{\"question\":\"How is tumor heterogeneity measured in the ex vivo experiments?\",\"answer\":\"Interpatient heterogeneity is quantified using the statistical variability of EC50 values derived from the ratio of upper and lower interdecile values.\"},{\"question\":\"Which drugs showed the largest variability in single-agent responses?\",\"answer\":\"Gemcitabine exhibited the highest single-agent heterogeneity across the cohort, while doxorubicin and olaparib showed more consistent responses but limited efficacy in many samples.\"}]","Heterogeneity of Ex Vivo Tumor Responses in Ovarian Cancer Tissues | PDF",1790088980,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d70ed3da2e6ab80bda70592f6a010cd.webp",983,1291,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/166512f56501d072d725aaee237f1116.webp",982,1290,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f9a7d81effa8151ede38ee264aa94330.webp",981,1289,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/384fc6a9748685681f6395d3debcfc78.webp",980,1287]